SCHEMBL3300571

SCHEMBL3300571

COc1ccc(CNc2nc3c(c(=O)n2-c2cccnc2)CN(C(=O)Nc2ccc(F)c(F)c2)CC3)cc1

nearest known ligand 0.43

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
PRLHR P49683 5/20 0.43
PDE10A Q9Y233 3/20 0.43
NAMPT P43490 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3298474 0.92 PRLHR (0.45) PRLHRPDE10A
SCHEMBL3298754 0.92 PRLHR (0.45) PRLHRPDE10ANAMPT
SCHEMBL3298991 0.92 PRLHR (0.47) PRLHRPDE10ANAMPT
SCHEMBL3298674 0.90 PRLHR (0.47) PRLHR
SCHEMBL3297733 0.90 PRLHR (0.44) PRLHRPDE10ANAMPT
SCHEMBL3301520 0.90 PRLHR (0.43) PRLHRPDE10A
SCHEMBL3297673 0.89 PRLHR (0.45) PRLHRNAMPT
SCHEMBL3300101 0.89 PRLHR (0.44) PRLHRPDE10A
SCHEMBL3294298 0.89 PRLHR (0.45) PRLHRNAMPT
SCHEMBL3300656 0.89 PRLHR (0.52) PRLHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8232282-B2 Compound having bicyclic pyrimidine structure and pharmaceutical composition comprising the same DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2012-07-31 US disclosed
US-20100093771-A1 Compound having bicyclic pyrimidine structure and pharmaceutical composition comprising the same SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2010-04-15 US disclosed
EP-2078719-A1 COMPOUND HAVING BICYCLIC PYRIMIDINE STRUCTURE AND PHARMACEUTICAL COMPOSITION COMPRISING THE COMPOUND Dainippon Sumitomo Pharma Co., Ltd. (JP) 2009-07-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100093771-A1 Compound having bicyclic pyrimidine structure and pharmaceutical composition comprising the same GART, MGAT2, MGAT1 PRLHR 3093/4885PDE10A 2176/4885NAMPT 115/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.